Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer

NCT00408460 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00408460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
October 31, 2012
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural effusion, recurrent non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer